| __timestamp | Neurocrine Biosciences, Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 7459000 |
| Thursday, January 1, 2015 | 81491000 | 11831000 |
| Friday, January 1, 2016 | 94291000 | 25705000 |
| Sunday, January 1, 2017 | 121827000 | 46181000 |
| Monday, January 1, 2018 | 160524000 | 59497000 |
| Tuesday, January 1, 2019 | 200000000 | 65003000 |
| Wednesday, January 1, 2020 | 275000000 | 74506000 |
| Friday, January 1, 2021 | 328100000 | 126006000 |
| Saturday, January 1, 2022 | 463800000 | 126215000 |
| Sunday, January 1, 2023 | 565000000 | 120161000 |
| Monday, January 1, 2024 | 731100000 |
Igniting the spark of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Neurocrine Biosciences, Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D spending. From 2014 to 2023, Neurocrine Biosciences increased its R&D expenses by over 1,100%, peaking at $565 million in 2023. This robust growth underscores their commitment to pioneering treatments and therapies.
Conversely, Protagonist Therapeutics, while also increasing its R&D investments, saw a more modest growth of approximately 1,500%, reaching $120 million in 2023. This disparity highlights the varying scales and strategies within the biotech sector. As these companies continue to innovate, their R&D investments will play a crucial role in shaping the future of healthcare.
Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Neurocrine Biosciences, Inc.
AbbVie Inc. or Protagonist Therapeutics, Inc.: Who Invests More in Innovation?
Vertex Pharmaceuticals Incorporated or Neurocrine Biosciences, Inc.: Who Invests More in Innovation?
Regeneron Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.: Strategic Focus on R&D Spending
United Therapeutics Corporation vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Verona Pharma plc
Research and Development Expenses Breakdown: Neurocrine Biosciences, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Soleno Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Novavax, Inc.
Research and Development: Comparing Key Metrics for Insmed Incorporated and Protagonist Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Alkermes plc and Protagonist Therapeutics, Inc.
R&D Insights: How Protagonist Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated Allocate Funds